Основная статистика
| LEI | 5493003CK9Y2H0OORR73 |
| CIK | 1379006 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to NanoViricides, Inc.
SEC Filings (Chronological Order)
На этой странице представлен полный хронологический список документов SEC, за исключением документов о собственности, которые мы предоставляем в других местах.
| May 15, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2025 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) Delaware 76-0674577 (State or other jurisdiction) (IRS Employer |
|
| February 14, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2024 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) Delaware 76-0674577 (State or other jurisdiction) (IRS Emplo |
|
| December 12, 2024 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 7, 2024 NANOVIRICIDES, INC. |
|
| November 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2024 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) Delaware 76-0674577 (State or other jurisdiction) (IRS Empl |
|
| October 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy State |
|
| September 27, 2024 |
NanoViricides, Inc. Insider Trading Policy effective September 20, 2024 Exhibit 19.1 NanoViricides, Inc. Policy on Insider Trading This Insider Trading Policy describes the standards of NanoViricides, Inc. (the “Company”) on trading, and causing the trading of, the Company’s securities or securities of certain other publicly traded companies while in possession of confidential information. This Policy is divided into two parts: the first part prohibits trading in cert |
|
| September 27, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2024 Commission File Number 001-36081 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) DELAWARE 76-0674577 (State or other jurisdiction of incorporation or organizati |
|
| September 27, 2024 |
Amendment to Line of Credit Agreement dated Exhibit 10.34 AMENDMENT TO LINE OF CREDIT AGREEMENT This AMENDMENT TO LINE OF CREDIT AGREEMENT (this “Amendment”), dated as of the 20th day of September, 2024 (the “Effective Date”), is entered into by Anil R. Diwan and/or his successors and assigns (collectively, the “Lender”) and NanoViricides, Inc., a Delaware corporation (“Borrower”). Lender and Borrower are each referred to herein individuall |
|
| August 9, 2024 |
Extension of Employment Agreement with Anil Diwan effective July 1, 2024 EXHIBIT 10.1 EXTENSION TO EMPLOYMENT AGREEMENT This Extension to Employment Agreement (the “Extension”) effective as of July 1, 2024, between Anil R. Diwan, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the Company,” and collectively with the Employee, the “Parties”). WHEREAS, |
|
| August 9, 2024 |
NANOVIRICIDES, INC. Up to $ $9,318,576 of Common Stock AMENDMENT NO. 1 DATED AUGUST 9, 2024 To Prospectus Supplement dated April 5, 2024 (To Prospectus Dated May 22, 2023) Filed pursuant to Rule 424(b)(5) Registration No. 333-271706 NANOVIRICIDES, INC. Up to $ $9,318,576 of Common Stock This Amendment No. 1 to Prospectus Supplement (the “Amendment”) amends and supplements the information in our prospectus, dated May 22, 2023 (the “Prospectus”), and th |
|
| August 9, 2024 |
Extension of Employment Agreement with Meeta EXHIBIT 10.2 EXTENSION TO CHIEF FINANCIAL OFFICER EMPLOYMENT AGREEMENT This Extension to Employment Agreement (the “Extension”) effective as of July 1, 2024, between MEETA VYAS, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the Company,” and collectively with the Employee, the |
|
| August 9, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 5, 2024 NANOVIRICIDES, INC. |
|
| May 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) Delaware 76-0674577 (State or other jurisdiction) (IRS Employer |
|
| May 8, 2024 |
“Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Issuer, “NNVC” “Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Issuer, “NNVC” www.nanoviricides.com May 8, 2024 Division of Corporation Finance, Office of Life Sciences United States Securities and Exchange Commission Washington, D.C. 20549 Re: NanoViricides, Inc. Form 10-K for Fiscal Year Ended June 30, 2023 Filed October 13, 2023 Response dated April 9, 2024 File No. 001-36081 Ladies and Gentleme |
|
| April 9, 2024 |
“Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Issuer, “NNVC” “Nanotechnology-Enabled Targeted Viricides” A Publicly Traded Issuer, “NNVC” www.nanoviricides.com April 9 2024 Division of Corporation Finance, Office of Life Sciences United States Securities and Exchange Commission Washington DC 20549 Re: NanoViricides, Inc. Form 10-K for Fiscal Year Ended June 30, 2023 Filed October 13, 2023 File No. 001-36081 Ladies and Gentlemen: Please be advised that the u |
|
| April 5, 2024 |
At Market Issuance Sales Agreement by and between NanoViricides, Inc. and EF Hutton LLC Exhibit 1.1 NANOVIRICIDES, INC. Common Stock (par value $0.00001 per share) At Market Issuance Sales Agreement April 5, 2024 EF Hutton LLC 590 Madison Avenue, 39th Floor New York, New York 10022 Ladies and Gentlemen: NanoViricides, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with EF Hutton LLC (the “Agent”) as follows: 1. Issuance and Sale o |
|
| April 5, 2024 |
NANOVIRICIDES, INC. Up to $5,049,574 of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated May 22, 2023 and Prospectus Supplement dated August 7, 2023) Registration No. |
|
| April 5, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) April 5, 2024 NANOVIRICIDES, INC. |
|
| February 16, 2024 |
Line of Credit Agreement between NanoViricides, Inc. and Dr. Anil R. Diwan, dated November 13, 2023 Exhibit 10.3 LINE OF CREDIT AGREEMENT THIS LINE OF CREDIT AGREEMENT (“Agreement”) is made and entered into effective as of the 13th day of November, 2023 (“Effective Date”) by and among Anil R. Diwan and/or his successors and assigns (collectively, the “Lender”) and NanoViricides, Inc., a Delaware Corporation (the “Borrower”). R E C I T A L S: A. The Borrower wishes to obtain from the Lender, a li |
|
| February 16, 2024 |
Extension Agreement between the Company and Dr. Anil R. Diwan, dated February 12, 2024 Exhibit 10.4 LINE OF CREDIT EXTENSION AGREEMENT THIS EXTENSION AGREEMENT (the “Extension”) is dated February 12, 2024 by and between NANOVIRICIDES, INC., a Delaware corporation (“Borrower”), and ANIL R. DIWAN, (“Lender”). R E C I T A L S A. Borrower and Lender entered into that certain Line of Credit Agreement (“LOC Agreement”) dated November 8, 2023, pursuant to which Lender agreed to extend to B |
|
| February 16, 2024 |
Letter from TheraCour Pharma, Inc. Exhibit 10.5 February 12, 2024. Meeta Vyas, CFO Nanoviricides, Inc. 1 Controls Drive Shelton, CT 06484 Dear Ms. Vyas, Nanoviricides, Inc. has requested that TheraCour Pharma, Inc. (“TheraCour”) apply the current $500,000 advance now being held by TheraCour against current and unpaid invoices it has issued to Nanoviricides, Inc. Nanoviricides has further requested that TheraCour suspend the require |
|
| February 16, 2024 |
Amendment to License Agreement between NanoViricides, Inc. and TheraCour, dated February 13, 2024 Exhibit 10.2 AMENDMENT TO LICENSE AGREEMENT This AMENDMENT TO LICENSE AGREEMENT (this “Amendment”), dated as of the 13 day of February, 2024 (the “Effective Date”), is entered into by TheraCour Pharma, Inc., a Connecticut corporation (“Licensor”) and NanoViricides, Inc., a Delaware corporation (the “Licensee”). Licensor and Licensee are each referred to herein individually as a “Party” and collect |
|
| February 16, 2024 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 12, 2024 NANOVIRICIDES, INC. |
|
| February 14, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2023 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) Delaware 76-0674577 (State or other jurisdiction) (IRS Emplo |
|
| January 19, 2024 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 13, 2024 NANOVIRICIDES, INC. |
|
| December 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Defin |
|
| November 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2023 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) Delaware 76-0674577 (State or other jurisdiction) (IRS Empl |
|
| November 7, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 6, 2023 NANOVIRICIDES, INC. |
|
| October 13, 2023 |
Extension to CFO Agreement with Meeta Vyas effective July 1, 2023 Exhibit 10.26 EXTENSION TO CHIEF FINANCIAL OFFICER EMPLOYMENT AGREEMENT This Extension to Employment Agreement (the “Extension”) effective as of July 1, 2023, between MEETA VYAS, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the Company,” and collectively with the Employee, the |
|
| October 13, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2023 Commission File Number 001-36081 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) DELAWARE 76-0674577 (State or other jurisdiction of incorporation or organizati |
|
| October 13, 2023 |
Extension to Employment Agreement with A. Diwan effective July 1, 2023 Exhibit 10.25 EXTENSION TO EMPLOYMENT AGREEMENT This Extension to Employment Agreement (the “Extension”) effective as of July 1, 2023, between Anil R. Diwan, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the Company,” and collectively with the Employee, the “Parties”). WHEREAS, |
|
| September 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 001-36081 FORM 12b-25 NOTIFICATIONS OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2023 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transiti |
|
| September 1, 2023 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) August 29, 2023 NANOVIRICIDES, INC. |
|
| September 1, 2023 |
Deferred Expense Exchange Agreement between NanoViricides, Inc. and TheraCour Pharma, Inc. EXHIBIT 10.2 DEFERRED EXPENSE EXCHANGE AGREEMENT This DEFERRED EXPENSE EXCHANGE AGREEMENT (this “Exchange Agreement”), effective of July 19, 2023 (“Execution Date”), by and between NanoViricides, Inc., a Nevada corporation (the “Company”) and TheraCour Pharma, Inc., a Connecticut corporation (“TheraCour”) (collectively, the “Parties”). WHEREAS, pursuant to the Licensing Agreement dated September 7 |
|
| September 1, 2023 |
EXHIBIT 10.3 THIS NOTE AND THE SECURITIES ISSUABLE UPON ITS CONVERSION HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR THE SECURITIES LAWS OF ANY STATE AND MAY NOT BE SOLD, TRANSFERRED, ASSIGNED OR OTHERWISE DISPOSED OF WITHOUT REGISTRATION UNDER THE SECURITIES ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR AN OPINION OF COUNSEL, REASONABLY SATISFA |
|
| August 7, 2023 |
NANOVIRICIDES, INC. Up to $5,713,022 of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated May 5, 2023) Registration No. |
|
| May 25, 2023 |
Plan of Conversion of NanoViricides, Inc. into NanoViricides, Inc. dated May 22, 2023 Exhibit 2.1 PLAN OF CONVERSION OF NANOVIRICIDES, INC. A Nevada Corporation INTO NANOVIRICIDES, INC. A Delaware Corporation THIS PLAN OF CONVERSION, dated as of May 22, 2023, (including all of the Exhibits attached hereto, this “Plan”), is hereby adopted by NanoViricides, Inc., a Nevada corporation, in order to set forth the terms, conditions and procedures governing the conversion of NanoViricides |
|
| May 25, 2023 |
Other Events, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 25, 2023 NANOVIRICIDES, INC. |
|
| May 17, 2023 |
May 17, 2023 Via Edgar Only United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| May 15, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2023 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer I |
|
| May 8, 2023 |
As filed with the Securities and Exchange Commission on May 8, 2023 As filed with the Securities and Exchange Commission on May 8, 2023 Registration Statement No. |
|
| May 5, 2023 |
Exhibit 4.3 NANOVIRICIDES, INC. AND , TRUSTEE INDENTURE DATED AS OF , 2023 DEBT SECURITIES NANOVIRICIDES, INC. RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939 AND INDENTURE, DATED AS OF , 2023 Section of Trust Indenture Act of 1939 Section(s) of Indenture § 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 § 311(a) 613 (b) 613 (c) Not Applicabl |
|
| May 5, 2023 |
As filed with the Securities and Exchange Commission on May 5, 2023 As filed with the Securities and Exchange Commission on May 5, 2023 Registration Statement No. |
|
| May 5, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) NanoViricides, Inc. |
|
| March 31, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 27, 2023 NANOVIRICIDES, INC. |
|
| March 31, 2023 |
License Agreement with Karveer Meditech Private Limited Exhibit 10.1 PORTIONS OF THE EXHIBIT HAVE BEEN OMITTED FROM THIS EXHIBIT 10.1 SINCE THE INFORMATION IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT CUSTOMARILY AND ACTUALLY TREATS AS PRIVATE AND CONFIDENTIAL. LICENSE AGREEMENT THIS LICENSE AGREEMENT (the "Agreement") is made at Kolhapur on March 10, 2023 by and Between NANOVIRICIDES, INC. a Company incorporated under the la |
|
| February 14, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 1320 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2022 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employe |
|
| February 13, 2023 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 7, 2023 NANOVIRICIDES, INC. |
|
| December 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement |
|
| December 22, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 17, 2022 NANOVIRICIDES, INC. |
|
| November 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| November 14, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 4, 2022 |
PRE 14A 1 tm2228941d1pre14a.htm PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 1 |
|
| October 13, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| October 11, 2022 |
Extension to Employment Agreement with A. Diwan Exhibit 10.2 EXTENSION TO EMPLOYMENT AGREEMENT This Extension to Employment Agreement (the ?Extension?) effective as of July 1, 2022, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (?Employee?), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (?the Company,? and collectively with the Employee, the ?Parties?). WHEREAS, |
|
| October 11, 2022 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) October 6, 2022 NANOVIRICIDES, INC. |
|
| September 29, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 001-36081 FORM 12b-25 NOTIFICATIONS OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2022 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Transiti |
|
| May 16, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 14, 2022 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 26, 2021 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 20, 2021 NANOVIRICIDES, INC. |
|
| November 15, 2021 |
Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2021 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) NEVADA 76-0674577 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 CONTROLS D |
|
| October 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| September 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 001-36081 FORM 12b-25 NOTIFICATIONS OF LATE FILING (Check One): x Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q ? Form N-SAR ? Form N-CSR For Period Ended: June 30, 2021 ?Transition Report on Form 10-K ?Transition Report on Form 20-F ?Transition Report on Form 11-K ?Transition Report on Form 10-Q ?Transition Re |
|
| September 21, 2021 |
Exhibit 99.1 Significantly Improved Safety Profile and Metabolism of Remdesivir Observed Due to Encapsulation in NanoViricides Drug Candidate Enabling Potential Highly Effective Pan-Coronavirus Antiviral Drug Shelton, Connecticut - September 21, 2021 - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nan |
|
| September 21, 2021 |
Regulation FD Disclosure, Other Events, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 21, 2021 NANOVIRICIDES, INC. |
|
| September 15, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported): September 9, 2021 NANOVIRICIDES, INC. |
|
| September 15, 2021 |
Extension of Employment Agreement with Anil Diwan Exhibit 10.2 EXTENSION TO EMPLOYMENT AGREEMENT This Extension to Employment Agreement (the ?Extension?) effective as of July 1, 2021, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (?Employee?), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (?the Company,? and collectively with the Employee, the ?Parties?). WHEREAS, |
|
| September 15, 2021 |
Exhibit 99.1 NanoViricides Completes Licensing for Coronavirus Field which Includes Current COVID-19 Drug Development Shelton, Connecticut - September 14, 2019 - NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has completed the process of licensing the human Coronavirus field for drug development and commercializatio |
|
| September 15, 2021 |
License Agreement dated September 7, 2021 between NanoViricides, Inc. and TheraCour Pharma, Inc. Exhibit 10.1 LICENSE AGREEMENT This LICENSE AGREEMENT (?Agreement?) is made and entered into as of the 7th day of September, 2021 (the ?Agreement Date?) by and between TheraCour Pharma, Inc., a Connecticut corporation (?Licensor?) and NanoViricides, Inc., a Nevada corporation (?Licensee?). Licensor and Licensee are each referred to herein individually, as a ?Party? and collectively, as the ?Partie |
|
| May 14, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2021 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) o |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2020 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No. |
|
| February 16, 2021 |
CUSIP No: 630087302 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. 1)* NanoViricides, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 630087302 (CUSIP Number) |
|
| February 12, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* NanoViricides, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 630087302 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| February 12, 2021 |
Joint Acquisition Statement Pursuant to Section 240.13d-1(k) Altium Capital Management, LP SC 13G/A EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240. |
|
| January 26, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* NanoViricides, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 630087302 (CUSIP Number) December 31, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this |
|
| December 10, 2020 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 5, 2020 NANOVIRICIDES, INC. |
|
| December 3, 2020 |
NANOVIRICIDES, INC. Up to $13,667,676 of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated April 2, 2020 and the Prospectus Supplement dated July 31, 2020) Registration No. |
|
| November 19, 2020 |
NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA Exhibit 99.1 NanoViricides Strengthens its Board of Directors with Addition of Industry Veteran Brian Zucker, CPA SHELTON, CONNECTICUT - November 19, 2020 - NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Mr. Brian Zucker, CPA, has joined the Company’s Board of Directors, effective November 13, 2020, a |
|
| November 19, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 13, 2020 NANOVIRICIDES, INC. |
|
| November 19, 2020 |
Director Retainer Agreement dated November 13, 2020 between NanoViricides, Inc. and Brian Zucker Exhibit 10.1 NANOVIRICIDES, INC. DIRECTOR RETAINER AGREEMENT THIS DIRECTOR RETAINER AGREEMENT (“Agreement”) is entered into by and between NanoViricides, Inc., a Nevada corporation (“Corporation”) and Brian Zucker (“Director”) as of November , 2020. WHEREAS, Director has been duly appointed to the Corporation’s Board of Directors to be elected as a Class II Director, in accordance with the Corpora |
|
| November 16, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2020 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No |
|
| October 26, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| October 13, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2020 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) NEVADA 76-0674577 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 CONTROLS D |
|
| September 28, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 001-36081 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): x Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form N-SAR ¨ Form N-CSR For Period Ended: June 30, 2020 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transitio |
|
| September 4, 2020 |
Regulation FD Disclosure, Financial Statements and Exhibits - FORM 8-K SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 3, 2020 NANOVIRICIDES, INC. |
|
| September 4, 2020 |
Exhibit 99.1 NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conference Shelton, CT / ACCESSWIRE / September 4, 2020/ - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today reported on t |
|
| August 3, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 31, 2020 NANOVIRICIDES, INC. |
|
| August 3, 2020 |
Exhibit 1.1 NANOVIRICIDES, INC. Common Stock (par value $0.001 per share) At Market Issuance Sales Agreement July 31, 2020 B. Riley Securities, Inc. 299 Park Avenue, 21st Floor New York, NY 10171 Kingswood Capital Markets, a division of Benchmark Investments, Inc. 17 Battery Place, Suite 625 New York, New York 10004 Ladies and Gentlemen: NanoViricides, Inc., a Nevada corporation (the “Company”), c |
|
| July 31, 2020 |
NANOVIRICIDES, INC. Up to $50,000,000 of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated April 2, 2020) Registration No. |
|
| July 20, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NanoViricides, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 630087302 (CUSIP Number) July 9, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to wh |
|
| July 13, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 8, 2020 NANOVIRICIDES, INC. |
|
| July 13, 2020 |
NANOVIRICIDES CLOSES ON $11.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 NANOVIRICIDES CLOSES ON $11.5 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SHELTON, CONNECTICUT — Monday, July 13, 2020 - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has completed an underwritten public offering (the “Offerin |
|
| July 13, 2020 |
Exhibit 10.1 UNDERWRITING AGREEMENT between NANOVIRICIDES, INC. and KINGSWOOD CAPITAL MARKETS, A DIVISION OF BENCHMARK INVESTMENTS INC., as Representative of the Several Underwriters NANOVIRICIDES, INC. UNDERWRITING AGREEMENT New York, New York July 9, 2020 Kingswood Capital Markets, a division of Benchmark Investments, Inc. As Representative of the several Underwriters named on Schedule 1 attache |
|
| July 9, 2020 |
SUBJECT TO COMPLETION, DATED JULY __, 2020 NANOVIRICIDES, INC. [_____] Shares Of Common Stock PRELIMINARY PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus March 26, 2020) Registration No. |
|
| July 9, 2020 |
NANOVIRICIDES, INC. 1,369,863 Shares Of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus March 26, 2020) Registration No. |
|
| June 22, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2020 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) o |
|
| June 4, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 29, 2020 NANOVIRICIDES, INC. |
|
| May 29, 2020 |
NNVC / NanoViricides, Inc. / CVI Investments, Inc. - SC 13G Passive Investment CUSIP No: 630087302 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2. (Amendment No. )* NanoViricides, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title of Class of Securities) 630087302 (CUSIP Number) M |
|
| May 22, 2020 |
Exhibit 10.2 May 21, 2020 Mr. Anil Diwan Chairman and President Nanoviricides Inc. 1 Controls Drive Shelton, CT 06484 Dear Mr. Diwan: This letter (the “Agreement”) constitutes the agreement among Maxim Group LLC (“Maxim”) , Kingswood Capital Markets, a division of Benchmark Investments, Inc. (“Kingswood” and collectively with Maxim, the “Placement Agents”) and Nanoviricides, Inc., a company incorp |
|
| May 22, 2020 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of May 21, 2020, between NanoViricides, Inc. a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| May 22, 2020 |
NANOVIRICIDES, INC. 1,400,000 Shares Of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus March 26, 2020) Registration No. |
|
| May 22, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 21, 2020 NANOVIRICIDES, INC. |
|
| May 22, 2020 |
NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering Exhibit 99.1 NanoViricides Announces Pricing of $10.2 Million Registered Direct Offering Shelton, Connecticut - May 21, 2020 - NanoViricides, Inc. (NYSE American: NNVC) (the "Company"), a leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has entered into a securities purchase agreement with several institutional inves |
|
| May 19, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): May 15, 2020 NANOVIRICIDES, INC. |
|
| May 19, 2020 |
Director Retainer Agreement, dated as of May 15, 2020, between NanoViricides, Inc. and Todd Rokita Exhibit 10.1 NANOVIRICIDES, INC. DIRECTOR RETAINER AGREEMENT THIS DIRECTOR RETAINER AGREEMENT (“Agreement”) is entered into by and between NanoViricides, Inc., a Nevada corporation (“Corporation”) and Todd Rokita (“Director”) as of May , 2020. WHEREAS, Director has been duly appointed to the Corporation’s Board of Directors to be elected as a Class I Director, in accordance with the Corporation’s |
|
| May 19, 2020 |
Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. Exhibit 99.1 Honorable Ex-Congressman Todd Rokita Joins the Board of Directors of NanoViricides, Inc. SHELTON, CONNECTICUT - May 18, 2019 - NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a leader in developing novel nanomedicines to treat viral diseases, announced today that Honorable Mr. Todd Rokita, J.D., former member of the U.S. House of Representatives from Indiana, has joined the Co |
|
| May 14, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 14, 2020 NANOVIRICIDES, INC. |
|
| March 31, 2020 |
March 31, 2020 Via Edgar Only United States Securities and Exchange Commission Mail Stop 6010 Washington, D. |
|
| March 24, 2020 |
Exhibit 4.3 NANOVIRICIDES, INC. AND , TRUSTEE INDENTURE DATED AS OF , 2020 DEBT SECURITIES NANOVIRICIDES, INC. RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939 AND INDENTURE, DATED AS OF , 2020 Section of Trust Indenture Act of 1939 Section(s) of Indenture § 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 § 311(a) 613 (b) 613 (c) Not Applicabl |
|
| March 24, 2020 |
NNVC / NanoViricides, Inc. S-3 - - FORM S-3 As filed with the Securities and Exchange Commission on March 24, 2020 Registration Statement No. |
|
| March 24, 2020 |
Audited Financial Statements of NanoViricides, Inc. as of June 30, 2019 and June 30, 2018 Exhibit 99.1 REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM To the Board of Directors and Stockholders of NanoViricides, Inc. Opinion on the Financial Statements We have audited the accompanying balance sheets of NanoViricides, Inc. (the "Company") as of June 30, 2019 and 2018, and the related statements of operations, changes in stockholders' equity, and cash flows for each of the years |
|
| March 20, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) March 16, 2020 NANOVIRICIDES, INC. |
|
| March 20, 2020 |
Exhibit 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Amendment (PURSUANT TO NRS 78.385 AND 78.390) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Articles of Incorporation For Nevada Profit Corporations (Pursuant to NRS 78.385 and 78.390 - |
|
| February 19, 2020 |
NNVC / NanoViricides, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2019 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No. |
|
| February 11, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 7, 2020 NANOVIRICIDES, INC. |
|
| February 11, 2020 |
Director Retainer Agreement between NanoViricides, Inc. and Makarand Jawadekar EXHIBIT 10.1 NANOVIRICIDES, INC. DIRECTOR RETAINER AGREEMENT THIS DIRECTOR RETAINER AGREEMENT (“Agreement”) is entered into by and between NanoViricides, Inc., a Nevada corporation (“Corporation”) and Makarand Jawadekar (“Director”) as of , 2020. WHEREAS, Director has been duly appointed to the Corporation’s Board of Directors to be elected as Class II, in accordance with the Corporation’s bylaws; |
|
| February 5, 2020 |
NNVC / NanoViricides, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement |
|
| January 28, 2020 |
Exhibit 10.2 EXCHANGE AGREEMENT EXCHANGE AGREEMENT (the "Agreement"), dated as of January 27, 2020 by and between NanoViricides, Inc., a Nevada corporation (the "Company"), the investor listed on the signature page attached hereto under the heading "Holder" (the "Holder" and together with the Company, the "Parties"). Capitalized terms used herein and not otherwise defined herein shall have the res |
|
| January 28, 2020 |
Form of Common Stock Purchase Warrant Exhibit 10.3 COMMON STOCK PURCHASE WARRANT Nanoviricides, inc. Warrant Shares: 173,611 Issue Date: February 27, 2019 Exchange Date: January 29, 2020 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, . or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or a |
|
| January 28, 2020 |
Form of Settlement Agreement and Mutual Release Exhibit 10.1 SETTLEMENT AGREEMENT AND MUTUAL RELEASE This Settlement Agreement and Mutual Release (“AGREEMENT”) is entered into as of January 24, 2020 by and among Hudson Bay Master Fund Ltd., a company formed under the laws of the Cayman Islands, (“HUDSON BAY”); Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B, a company formed under the laws of the Cayman Islands (“ALTO”), and N |
|
| January 28, 2020 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 27, 2020 NANOVIRICIDES, INC. |
|
| January 27, 2020 |
NNVC / NanoViricides, Inc. / Empery Asset Management, LP - NANOVIRICIDES, INC. Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* NanoViricides, Inc. (Name of Issuer) Common Stock, $0.001 par value (Title of Class of Securities) 630087302 (CUSIP Number) January 22, 2020 (Date of event which requires filing of this statement) Check the appropriate box to designate the rule pursuant to which this S |
|
| January 27, 2020 |
Underwriting with Aegis Capital Corp. dated January 21, 2020 Exhibit 10.1 2,500,000 SHARES OF COMMON STOCK OF NANOVIRICIDES, INC. UNDERWRITING AGREEMENT January 21, 2020 Aegis Capital Corp. 810 Seventh Avenue New York, NY 10019 As Representative of the several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, NanoViricides, Inc., a company incorporated under the laws of Nevada (collectively with its subsidiaries and aff |
|
| January 27, 2020 |
NANOVIRICIDES CLOSES ON $8.625 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK Exhibit 99.1 NANOVIRICIDES CLOSES ON $8.625 MILLION UNDERWRITTEN PUBLIC OFFERING OF COMMON STOCK SHELTON, CONNECTICUT — Friday, January 24, 2020 - NanoViricides, Inc. (NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today announced that it has completed an underwritten public offering (the “Off |
|
| January 27, 2020 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits, Other Events SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 21, 2020 NANOVIRICIDES, INC. |
|
| January 24, 2020 |
Filed Pursuant to Rule 424(b)(1) Registration Number 333-235306 PROSPECTUS 2,500,000 shares Common Stock We are offering 2,500,000 shares of our common stock in a firm commitment underwritten public offering based at the public offering price of $3. |
|
| January 9, 2020 |
NNVC / NanoViricides, Inc. CORRESP - - January 9, 2020 U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: NanoViricides, Inc. Registration Statement on Form S-1, as amended File No. 333-235306 Ladies and Gentlemen: As representative of the underwriters of the proposed public offering of common stock of NanoViricides, Inc. (the “Company”), we hereby join the Company’s re |
|
| January 8, 2020 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.3 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| January 8, 2020 |
NNVC / NanoViricides, Inc. CORRESP - - Publicly Traded Company, “NNVC” www.nanoviricides.com January 8, 2020 Via Edgar Only United States Securities and Exchange Commission Mail Stop 6010 Washington, D.C. 20549 Re: NanoViricides, Inc. Registration Statement on Form S-3 Filed on November 29, 2019 File No. 333-235306 To Whom It May Concern: Please be advised that the undersigned is the duly elected President and Chairman of NanoViricides |
|
| January 8, 2020 |
Form of Series A Conversion Waiver Exhibit 10.16 To Thursday, September 26, 2019. Attn: Re: Waiver Letter Regarding Conversion of Series A Shares Ladies and Gentlemen: Reference is made to that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”) of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this |
|
| January 8, 2020 |
Employment Agreement with M Vyas Exhibit 10.7 AGREEMENT AGREEMENT dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut. 1. Employment The Company agrees to employ Vyas, and Vyas hereby agrees to such employment, subject to the terms and condition |
|
| January 8, 2020 |
NNVC / NanoViricides, Inc. S-1/A - - FORM S-1/A As filed with the Securities and Exchange Commission on January 8, 2020 Registration No. |
|
| January 8, 2020 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.4 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| January 7, 2020 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.3 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| January 7, 2020 |
NNVC / NanoViricides, Inc. S-1/A - - FORM S-1/A As filed with the Securities and Exchange Commission on January 6, 2020 Registration No. |
|
| January 7, 2020 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.4 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| January 7, 2020 |
Form of Series A Conversion Waiver Exhibit 10.16 To Thursday, September 26, 2019. Attn: Re: Waiver Letter Regarding Conversion of Series A Shares Ladies and Gentlemen: Reference is made to that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”) of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this |
|
| January 7, 2020 |
Employment Agreement with M Vyas Exhibit 10.7 AGREEMENT AGREEMENT dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut. 1. Employment The Company agrees to employ Vyas, and Vyas hereby agrees to such employment, subject to the terms and condition |
|
| January 2, 2020 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 16, 2019 NANOVIRICIDES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 001-36081 76-0674577 (State or Other Jurisdiction of Incorporation) (Commission Fi |
|
| December 23, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.4 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| December 23, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.3 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| December 23, 2019 |
Form of Series A Conversion Waiver Exhibit 10.16 To Thursday, September 26, 2019. Attn: Re: Waiver Letter Regarding Conversion of Series A Shares Ladies and Gentlemen: Reference is made to that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”) of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this |
|
| December 23, 2019 |
NNVC / NanoViricides, Inc. S-1/A - - S-1/A As filed with the Securities and Exchange Commission on December 23, 2019 Registration No. |
|
| December 23, 2019 |
Employment Agreement with M Vyas Exhibit 10.7 AGREEMENT AGREEMENT dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut. 1. Employment The Company agrees to employ Vyas, and Vyas hereby agrees to such employment, subject to the terms and condition |
|
| December 19, 2019 |
Deferred Expense Exchange Agreement Exhibit 10.3 DEFERRED Expense EXCHANGE AGREEMENT This DEFERRED EXPENSE EXCHANGE AGREEMENT (this “Agreement”), is entered into as of December 17, 2019 (“Execution Date”), by and between NanoViricides, Inc., a Nevada corporation (the “Company”) and TheraCour Pharma, Inc., a Connecticut corporation (“TheraCour”) (collectively, the “Parties”). WHEREAS, pursuant to various license agreements between th |
|
| December 19, 2019 |
EXHIBIT 10.2 OPEN END MORTGAGE DEED To all People to Whom these Presents shall Come, Greeting: Know Ye, That NANOVIRICIDES, INC, a NEVADA corporation authorized to do business in the State of Connecticut of 1 Controls Drive, Shelton, CT (Grantor) for the consideration of TWO MILLION and 00/00 ($2,000,000.00) DOLLARS received to its full satisfaction of ANIL R. DIWAN, of (Grantee). DOES GIVE, GRANT |
|
| December 19, 2019 |
EXHIBIT 10.1 OPEN END MORTGAGE NOTE $2,000,000 December 16, 2019 FOR VALUE RECEIVED, NANOVIRICIDES, INC. (the ''Borrower"), a Nevada corporation with a mailing address of 1 Controls Drive, Shelton, CT, 06484 promises to pay to the order of ANIL R. DIWAN, AN INDIVIDUAL having a principal address at (the "Lender"), at such office or at such other place as the Lender may designate from time to time i |
|
| December 19, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 16, 2019 NANOVIRICIDES, INC. |
|
| December 17, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.3 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| December 17, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.4 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| December 17, 2019 |
NNVC / NanoViricides, Inc. S-1/A - - FORM S-1/A As filed with the Securities and Exchange Commission on December 15, 2019 Registration No. |
|
| December 17, 2019 |
Employment Agreement with M Vyas Exhibit 10.7 AGREEMENT AGREEMENT dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut. 1. Employment The Company agrees to employ Vyas, and Vyas hereby agrees to such employment, subject to the terms and condition |
|
| December 17, 2019 |
Slide © All Rights Reserved, NanoViricides, Inc., A Publicly Traded Company (NYSE - Amer.: NNVC) Slide ‹$OO5LJKWV5HVHUYHG1DQR9LULFLGHV,QF$3XEOLFO\7UDGHG&RPSDQ\ 1<6( $PHU 119& 3UHVHQWHGE\ $QLO5'LZDQ3K' 3UHVLGHQW ([HF&KDLUPDQ 0RELOH DGLZDQ#QDQRYLULFLGHVFRP “Bind - Encapsulate - Destroy” 1DQR9LULFLGHV¶7RSLFDO'UXJ&DQGLGDWH$JDLQVW6KLQJOHV 9=9 |
|
| December 17, 2019 |
Form of Series A Conversion Waiver Exhibit 10.16 To Thursday, September 26, 2019. Attn: Re: Waiver Letter Regarding Conversion of Series A Shares Ladies and Gentlemen: Reference is made to that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”) of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this |
|
| December 13, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 13, 2019 NANOVIRICIDES, INC. |
|
| December 13, 2019 |
Exhibit 99.1 NanoViricides President Dr. Anil Diwan Provides Responses to Shareholder Questions at the Annual Meeting of Shareholders SHELTON, CONNECTICUT - December 9, 2019 - NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, held its annual meeting of shareholders of the Company on Saturday, December 7th, 2019 at 10:00 a.m., Eastern Daylight |
|
| November 29, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.4 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| November 29, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.3 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| November 29, 2019 |
NNVC / NanoViricides, Inc. S-1 - Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on November 27, 2019 Registration No. |
|
| November 29, 2019 |
Form of Series A Conversion Waiver Exhibit 10.16 To Thursday, September 26, 2019. Attn: Re: Waiver Letter Regarding Conversion of Series A Shares Ladies and Gentlemen: Reference is made to that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”) of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this |
|
| November 29, 2019 |
Employment Agreement with M Vyas Exhibit 10.7 AGREEMENT AGREEMENT dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut. 1. Employment The Company agrees to employ Vyas, and Vyas hereby agrees to such employment, subject to the terms and condition |
|
| November 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2019 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No |
|
| November 14, 2019 |
NNVC / NanoViricides, Inc. NT 10-Q - - NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SEC FILE NUMBER 001-36081 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K x Form 10-Q ☐ Form N-SAR ☐ Form N-CSR For Period Ended: September 30, 2019 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Tran |
|
| November 6, 2019 |
NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development Exhibit 99.1 NanoViricides Completes Licensing for VZV Field which Includes Shingles Drug Development Shelton, Connecticut - November 4, 2019 - NanoViricides, Inc. (NYSE Amer.: NNVC) (the "Company"), a global leader in nanomedicines against viruses, announced today that it has completed the process of licensing the VZV (shingles and chickenpox virus) field for drug development and commercializatio |
|
| November 6, 2019 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 1, 2019 NANOVIRICIDES, INC. |
|
| November 6, 2019 |
License Agreement with TheraCour Pharma, Inc. Exhibit 10.1 LICENSE AGREEMENT This LICENSE AGREEMENT (“Agreement”) is made and entered into as of the 1st day of November, 2019 (the “Agreement Date”) by and between TheraCour Pharma, Inc., a Connecticut corporation (“Licensor”) and NanoViricides, Inc., a Nevada corporation (“Licensee”). Licensor and Licensee are each referred to herein individually, as a “Party” and collectively, as the “Parties |
|
| November 6, 2019 |
NNVC / NanoViricides, Inc. RW - - RW 1 Controls Drive, Shelton, CT 06484 November 5, 2019 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| October 28, 2019 |
NNVC / NanoViricides, Inc. DEF 14A - - DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| October 16, 2019 |
NNVC / NanoViricides, Inc. PRE 14A - - PRE 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ¨ Check the appropriate box: x Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Definitive Proxy Statement |
|
| September 28, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.4 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| September 28, 2019 |
Form of Series A Conversion Waiver Exhibit 10.16 To Thursday, September 26, 2019. Attn: Re: Waiver Letter Regarding Conversion of Series A Shares Ladies and Gentlemen: Reference is made to that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”) of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this |
|
| September 28, 2019 |
Form of Common Stock Purchase Warrant Exhibit 4.7 COMMON STOCK PURCHASE WARRANT NANOVIRICIDES, INC. Warrant Shares: [] Initial Exercise Date: [], 2019 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exe |
|
| September 28, 2019 |
NNVC / NanoViricides, Inc. S-1 - Registration Statement - FORM S-1 As filed with the Securities and Exchange Commission on September 27, 2019 Registration No. |
|
| September 28, 2019 |
Employment Agreement with M Vyas Exhibit 10.7 AGREEMENT AGREEMENT dated May 31, 2013, between NanoViricides, Inc. ("NanoViricides"), with its principal place of business at 135 Wood Street, Suite 205, West Haven, Connecticut, and Meeta Vyas ("Vyas"), residing at 155 Parsonage Road. Greenwich, Connecticut. 1. Employment The Company agrees to employ Vyas, and Vyas hereby agrees to such employment, subject to the terms and condition |
|
| September 28, 2019 |
Form of Representative’s Warrant Exhibit 4.8 EXHIBIT A Form of Representative’s Warrant Agreement THE REGISTERED HOLDER OF THIS PURCHASE WARRANT BY ITS ACCEPTANCE HEREOF, AGREES THAT IT WILL NOT SELL, TRANSFER, ASSIGN, PLEGDE OR HYPOTHECATE, OR BE THE SUBJECT OF ANY HEDGING, SHORT SALE, DERIVATIVE, PUT, OR CALL TRANSACTION THAT WOULD RESULT IN THE EFFECTIVE ECONOMIC DISPOSITION OF THIS PURCHASE WARRANT OR THE UNDERLYING SECURITIE |
|
| September 28, 2019 |
Form of Underwriting Agreement Exhibit 1.1 SHARES OF COMMON STOCK, PRE-FUNDED WARRANTS (EXERCISABLE FOR SHARES) AND WARRANTS (EXERCISABLE FOR SHARES) OF NANOVIRICIDES, INC. UNDERWRITING AGREEMENT [], 2019 Maxim Group LLC Investment Banking 405 Lexington Avenue, 2nd Fl. New York, New York 10174 As Representative of the Several underwriters, if any, named in Schedule I hereto Ladies and Gentlemen: The undersigned, NANOVIRICIDES, |
|
| September 28, 2019 |
Certificate of Amendment to Certificate of Designation of Series A Convertible Preferred Stock Exhibit 4.3 ROSS MILLER Secretary of State 204 North Carson Street Suite 1 Carson City, Nevada 99701-4520 (775) 684-5708 Website: www.nvsos.gov Amendment to Certificate of Designation After Issuance of Class or Series (PURSUANT TO NRS 78.1955) USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Amendment to Certificate of Designation For Nevada Profit Corporatio |
|
| September 28, 2019 |
Exhibit 4.6 PRE-FUNDED COMMON STOCK PURCHASE WARRANT NANOVIRICIDES, INC. Warrant Shares: [] Initial Exercise Date: [], 2019 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date he |
|
| September 26, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 22, 2019 NANOVIRICIDES, INC. |
|
| September 26, 2019 |
Exhibit 3.1 BARBARA K. CEGAVSKE Secretary of State 202 North Carson Street Carson City, Nevada 89701-4201 (775) 684-5708 Website: www.nvsos.gov Certificate of Change Pursuant to NRS 78.209 USE BLACK INK ONLY - DO NOT HIGHLIGHT ABOVE SPACE IS FOR OFFICE USE ONLY Certificate of Change filed Pursuant to NRS 78.209 For Nevada Profit Corporations 1. Name of corporation: NanoViricides, Inc. 2. The board |
|
| August 23, 2019 |
Form 10-K for the fiscal year ended June 30, 2019 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2019 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) NEVADA 76-0674577 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 CONTROLS D |
|
| August 1, 2019 |
Letter from Dr. Mukund Kulkarni Exhibit 17.1 From: Mukund Kulkarni, PhD, MBA July 31, 2019 To: Anil R. Diwan Chairman of the Board NanoViricides, Inc. Dear Anil, I have previously expressed my desire to retire from the Board of Directors of NanoViricides. Inc. to you and the other Board members due to health reasons. Now that a new member of the Board of Directors has been appointed, please consider this as my official resignati |
|
| August 1, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 31, 2019 NANOVIRICIDES, INC. |
|
| June 10, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) June 6, 2019 NANOVIRICIDES, INC. |
|
| June 10, 2019 |
Director Retainer Agreement, dated as of June 6, 2019, between the Registrant and Mark Day EXHIBIT 10.1 NANOVIRICIDES, INC. DIRECTOR RETAINER AGREEMENT THIS DIRECTOR RETAINER AGREEMENT (“Agreement”) is entered into by and between NanoViricides, Inc., a Nevada corporation (“Corporation”) and Mark Day (“Director”) as of June 6, 2019. WHEREAS, Director has been duly appointed to the Corporation’s Board of Directors to be elected as Class II, in accordance with the Corporation’s bylaws; and |
|
| May 15, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2019 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) o |
|
| March 1, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 27, 2019 NANOVIRICIDES, INC. (Exact name of registrant as specified in its charter) Nevada 001-36081 76-0674577 (State or other jurisdiction of incorporation or organization) |
|
| March 1, 2019 |
Letter Agreement with Chardan Capital Markets, LLC Exhibit 10.3 Chardan Capital Markets, LLC 17 State Street, Suite 1600 New York, New York 10004 February , 2019 CONFIDENTIAL Dr. Anil R. Diwan Preseident Nanoviricides, Inc. 1 Controls Drive Shelton, CT 06484 Dear Dr. Diwan: This letter (the “Agreement”) constitutes the agreement between Chardan Capital Markets, LLC (“Chardan”) (the “Placement Agent”) and Nanoviricides, Inc. (the “Company”), that P |
|
| March 1, 2019 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 27, 2019, between NanoViricides, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| March 1, 2019 |
NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering Exhibit 99.1 NanoViricides Announces $2.5 Million Financing in a Registered Direct Offering SHELTON, CONNECTICUT — Wednesday, February 27, 2019 — NanoViricides, Inc. (NYSE MKT: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the "Company"), announced today that it has entered into a securities purchase agreem |
|
| March 1, 2019 |
Exhibit 10.2 EXHIBIT C NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECT |
|
| March 1, 2019 |
NANOVIRICIDES, INC. 6,944,446 Shares Of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus March 1, 2017) Registration No. |
|
| February 14, 2019 |
NNVC / NanoViricides, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2018 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No. |
|
| February 1, 2019 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 1, 2019 NANOVIRICIDES, INC. |
|
| December 7, 2018 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) November 30, 2018 NANOVIRICIDES, INC. |
|
| November 14, 2018 |
NNVC / NanoViricides, Inc. FORM 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2018 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No |
|
| October 31, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) October 29, 2018 NANOVIRICIDES, INC. |
|
| October 31, 2018 |
Exhibit 10.1 NANOVIRICIDES, INC. DIRECTOR RETAINER AGREEMENT THIS DIRECTOR RETAINER AGREEMENT (“Agreement”) is entered into by and between NanoViricides, Inc., a Nevada corporation (“Corporation”) and James Sapirstein (“Director”) as of October , 2018. WHEREAS, Director has been duly appointed to the Corporation’s Board of Directors to be elected as a Director at the Corporation’s Annual Meeting o |
|
| October 19, 2018 |
NNVC / NanoViricides, Inc. DEFINITIVE PROXY STATEMENT UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Definitive Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Preliminary Proxy Statement |
|
| October 12, 2018 |
NNVC / NanoViricides, Inc. 10-K (Annual Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2018 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) NEVADA 76-0674577 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 CONTROLS D |
|
| October 12, 2018 |
NNVC / NanoViricides, Inc. / Boniuk Milton Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 28, 2018 |
NNVC / NanoViricides, Inc. NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36081 NOTIFICATION OF LATE FILING Form 10-K x Form 20-F ¨ Form 11-K ¨ Form 10-Q ¨ Form 10-D ¨ Form N-SAR ¨ Form N-CSR ¨ For Period Ended: June 30, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transition |
|
| September 11, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K/A (Amendment No. 1) CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) September 11, 2018 NANOVIRICIDES, INC. (Exact Name of Registrant as Specified in Its Charter) Nevada 000-1379006 76-0674577 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| September 11, 2018 |
Exhibit 17.2 KANE KESSLER, P.C. 666 THIRD AVENUE NEW YORK, NEW YORK 10017-4041 TEL 212.541.6222 FAX 212.245.3009 WWW.KANEKESSLER.COM WRITER’S DIRECT NUMBER 212-519-5109 WRITER’S EMAIL [email protected] August 7, 2018 Via Electronic and Regular Mail Dr. Milton Boniuk 1111 Hermann Drive, 29E Houston, TX 77004 Re: NanoViricides, Inc. Resignation of Duties Related to Non-Disclosure of Mater |
|
| July 23, 2018 |
Employment Agreement with Anil Diwan Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of July 1, 2018, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the Company”). WHEREAS, the parties hereto desire to enter into this Agreement in order to set forth the terms pur |
|
| July 23, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 19, 2018 NANOVIRICIDES, INC. |
|
| July 23, 2018 |
Employment Agreement with Irach Taraporewala Exhibit 10.2 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT (“Agreement”) dated as of July 19, 2018 (“Effective Date”), between IRACH B. TARAPOREWALA, 24 Carhart Ave. #204, White Plains, NY 10605 (“Employee”), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484 (“the Company”). WHEREAS, the parties hereto desire to enter into this Agreement in order to set forth t |
|
| July 19, 2018 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 11, 2018 NANOVIRICIDES, INC. |
|
| July 19, 2018 |
Exhibit 10.1 EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT ("Agreement") dated as of July 1, 2018, between ANIL R. DIWAN, c/o NanoViricides, Inc., 1 Controls Drive, Shelton, CT 06484 ("Employee"), and NanoViricides, Inc., a corporation with offices at 1 Controls Drive, Shelton, CT 06484("the Company"). WHEREAS, the parties hereto desire to enter into this Agreement in order to set forth the terms purs |
|
| July 10, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) July 3, 2018 NANOVIRICIDES, INC. |
|
| July 10, 2018 |
Exhibit 17.1 Milton Boniuk, M.D. 1111 Hermann Drive Unit 29E Houston, TX 77004 July 10, 2018 By E-mail Anil R. Diwan, President and Chairman Mukund S. Kulkarni, Director Stanley Glick, Director NanoViricides, Inc. 1 Controls Drive, Shelton, CT 06484 Dear Dr. Diwan and Members of the Board: After careful reflection, and based upon what appear to be irreconcilable disagreements between me, on the on |
|
| May 21, 2018 |
NNVC / NanoViricides, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2018 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) o |
|
| May 15, 2018 |
NNVC / NanoViricides, Inc. NT 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 001-36081 NOTIFICATION OF LATE FILING Form 10-K ¨ Form 20-F ¨ Form 11-K ¨ Form 10-Q x Form 10-D ¨ Form N-SAR ¨ Form N-CSR ¨ For Period Ended: March 31, 2018 ¨ Transition Report on Form 10-K ¨ Transition Report on Form 20-F ¨ Transition Report on Form 11-K ¨ Transition Report on Form 10-Q ¨ Transitio |
|
| May 4, 2018 |
Confidential Separation Agreement and General Release of Eugene Seymour EXHIBIT 10.1 CONFIDENTIAL SEPARATION AGREEMENT AND GENERAL RELEASE This Confidential Separation Agreement and General Release (“Agreement”) is made and entered into by NanoViricides, Inc., a corporation with offices located at 1 Controls Drive, Shelton, Connecticut 06484 (“Employer” or “Company”), and Eugene Seymour, who resides at 101 Ocean Avenue, Suite C800, Santa Monica, California 90402 (“Exe |
|
| May 4, 2018 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) May 1, 2018 NANOVIRICIDES, INC. |
|
| May 4, 2018 |
Form of Common Stock Purchase Warrant EXHIBIT 4.1 NEITHER THE ISSUANCE AND SALE OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE NOR THE SECURITIES INTO WHICH THESE SECURITIES ARE EXERCISABLE HAVE BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR APPLICABLE STATE SECURITIES LAWS. THE SECURITIES MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED OR ASSIGNED (I) IN THE ABSENCE OF (A) AN EFFECTIVE REGISTRATION STATEMENT FOR T |
|
| February 20, 2018 |
NNVC / NanoViricides, Inc. 10-Q (Quarterly Report) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2017 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No. |
|
| February 14, 2018 |
NNVC / NanoViricides, Inc. FORM 12B-25 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 SEC FILE NUMBER 333-206745 NOTIFICATION OF LATE FILING Form 10-K ? Form 20-F ? Form 11-K ? Form 10-Q x Form 10-D ? Form N-SAR ? Form N-CSR ? For Period Ended: December 31, 2017 ? Transition Report on Form 10-K ? Transition Report on Form 20-F ? Transition Report on Form 11-K ? Transition Report on Form 10-Q ? Trans |
|
| December 15, 2017 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 8, 2017 NANOVIRICIDES, INC. |
|
| November 22, 2017 |
NANOVIRICIDES, INC. 5,500,000 Shares Of Common Stock PROSPECTUS SUPPLEMENT Filed Pursuant to Rule 424(b)(5) (to Prospectus dated March 1, 2017) Registration No. |
|
| November 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2017 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No |
|
| November 8, 2017 |
NNVC / NanoViricides, Inc. DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Amendment No. 1) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definiti |
|
| October 27, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| September 28, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2017 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) NEVADA 76-0674577 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 CONTROLS D |
|
| May 15, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2017 Commission File Number: 001-36081 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) o |
|
| April 20, 2017 |
Nanotechnology-Enabled Targeted Viricides Publicly Traded Company, ?NNVC? www.nanoviricides.com April 20, 2017 Via Edgar Only United States Securities and Exchange Commission Mail Stop 6010 Washington, D.C. 20549 Re: NanoViricides, Inc. Registration Statement on Form S-3 Filed on March 1, 2017 File No. 333-216345 To Whom It May Concern: Please be advised that the undersigned is the duly elected Ch |
|
| April 18, 2017 |
Exhibit 4.3 NANOVIRICIDES, INC. AND , TRUSTEE INDENTURE DATED AS OF , 2017 DEBT SECURITIES NANOVIRICIDES, INC. RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939 AND INDENTURE, DATED AS OF , 2017 Section of Trust Indenture Act of 1939 Section(s) of Indenture ? 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 ? 311(a) 613 (b) 613 (c) Not Applicabl |
|
| April 18, 2017 |
As filed with the Securities and Exchange Commission on April 18, 2017 Registration Statement No. |
|
| April 18, 2017 |
April 18, 2017 VIA EDGAR ONLY United States Securities and Exchange Commission Mail Stop 4720 Washington, D. |
|
| March 1, 2017 |
Exhibit 4.3 NANOVIRICIDES, INC. AND , TRUSTEE INDENTURE DATED AS OF , 2017 DEBT SECURITIES NANOVIRICIDES, INC. RECONCILIATION AND TIE BETWEEN TRUST INDENTURE ACT OF 1939 AND INDENTURE, DATED AS OF , 2017 Section of Trust Indenture Act of 1939 Section(s) of Indenture ? 310(a)(1) 609 (a)(2) 609 (a)(3) Not Applicable (a)(4) Not Applicable (a)(5) 609 (b) 608, 610 ? 311(a) 613 (b) 613 (c) Not Applicabl |
|
| March 1, 2017 |
As filed with the Securities and Exchange Commission on February 28, 2017 Registration Statement No. |
|
| February 14, 2017 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2016 Commission File Number: 333-148471 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No |
|
| February 13, 2017 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) February 8, 2017 NANOVIRICIDES, INC. |
|
| February 13, 2017 |
EXHIBIT 99.1 PRESS RELEASE DATED FEBRUARY 13, 2017 NanoViricides Reports the Company?s Director Dr. Boniuk Converted Series B Debenture to Equity Effectively Raising $5M in New Equity for the Company SHELTON, CONNECTICUT ? February 13, 2017 - NanoViricides, Inc. (NYSE MKT: NNVC), a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform (the |
|
| February 13, 2017 |
Conversion and Settlement Agreement EXHIBIT 10.1 CONVERSION AND SETTLEMENT AGREEMENT CONVERSION AND SETTLEMENT AGREEMENT THIS CONVERSION AND SETTLEMENT AGREEMENT (this ?Agreement?) is dated February 8, 2017, by and between NANOVIRICIDES, INC. a Nevada corporation (the ?Company?), and [] (the ?Holder?), collectively the ?Parties?, and each individually, a ?Party?). RECITALS WHEREAS, on or about February 1, 2013, the Company issued a |
|
| December 15, 2016 |
Submission of Matters to a Vote of Security Holders SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) December 11, 2016 NANOVIRICIDES, INC. |
|
| November 14, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2016 Commission File Number: 333-148471 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification N |
|
| October 28, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definitive Proxy Statement |
|
| September 16, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2016 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) NEVADA 76-0674577 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 CONTROLS D |
|
| May 10, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2016 Commission File Number: 333-148471 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No.) |
|
| April 7, 2016 |
As filed with the Securities and Exchange Commission on April 7, 2016 Registration No. |
|
| February 9, 2016 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended December 31, 2015 Commission File Number: 333-148471 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification No |
|
| January 29, 2016 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of report (Date of earliest event reported) January 23, 2016 NANOVIRICIDES, INC. |
|
| December 8, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by Registrant x Filed by a Party other than the Registrant o Check the appropriate box: o Preliminary Proxy Statement o Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) x Definitive Proxy Statement |
|
| November 9, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended September 30, 2015 Commission File Number: 333-148471 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction) (IRS Employer Identification N |
|
| September 14, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE FISCAL YEAR ENDED JUNE 30, 2015 NANOVIRICIDES, INC. (Name of Business Issuer in Its Charter) NEVADA 76-0674577 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 1 CONTROLS D |
|
| July 24, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities and Exchange Act of 1934 PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): July 21, 2015 NANOVIRICIDES, INC. (Exact Name of Registrant as Specified in its Charter) Nevada 001-36081 76 |
|
| May 15, 2015 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 1934. For the quarterly period ended March 31, 2015 Commission File Number: 333-148471 NANOVIRICIDES, INC. (Exact name of Company as specified in its charter) NEVADA 76-0674577 (State or other jurisdiction (IRS Employer Identification No.) of i |
